- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05488977
The Effects of Endurance Training on Lipedema (LipidEx)
The Effects of Endurance Training in Women With Lipedema
Lipedema is a fat disorder causing accumulation of subcutaneous adipose tissue particularly in arms and legs, and predominantly affects women. Lipedema likely contributes to an array of other pathologies, including obesity, inflammatory bowel disease, and neurological disorders. Lipedema tissue is often very painful and can severely impair mobility. The condition can also increase the incidence of depression, anxiety, or eating disorders.
There seems to be a general impression that lipedema tissue is difficult to reduce by diet, exercise, or bariatric surgery. However, only a few studies have actually explored the effects of exercise training on lipedema. Despite the lack of knowledge, the existing guidelines for lipidemia treatment promote a healthy lifestyle with individually adjusted weight control measures, including physical activity. In general, exercise is known to have an important effect on adipose tissue. Excess adipose tissue causes macrophage infiltration into the adipose tissue leading to continuous low systemic inflammation. This would suggest that there is a systemic inflammatory response in lipedema patients. Increasing IL-6 levels with exercise can decrease the level of proinflammatory TNFalpha synthesized from adipocytes and therefore lead to an anti-inflammatory effect by increasing IL-10 and IL-1ra levels. IL-6 also stimulates fat oxidation by increasing lipolysis. For these reasons, adding an appropriate exercise program to standard treatment might provide additional benefits for lipedema patients. The investigators aim to determine the therapeutic potential of high-intensity interval training (HIIT) on pain, quality of life, body composition, cardiorespiratory fitness and circulating biomarkers in women with lipedema.
Study Overview
Detailed Description
Methods
Subjects 30 women diagnosed with lipedema age 18-65 will be randomized to (1:1) to 8 weeks of exercise training og a control group. Exclusion criteria includes ongoing eating disorders and/or orthopedic limitations for exercise training. A compliance with the training program of 80% will also be set as a criterion for completing the study. Participants will be recruited via social media, via physiotherapists, via posters at GPs and via a user representative from the Norwegian Lymphedema and Lipedema Association (NLLF). The master's students will obtain informed consent cf. GCP and the Health Research Act. The potential participants will have at least one week to consider their participation. If a research participant should be injured on the basis of something the investigators ask them to do, NTNU will have the insurance responsibility. The investigators will collect data on the type and stage of lipedema, when the participant was diagnosed. The investigators will also collect data on which clinical aids they are using and how often, e.g., compressions aids.
Intervention - Training protocol The women will be randomized (1:1) to 8 weeks of supervised high-intensity interval training (HIIT) that is 4×4 min intervals at 85-95% of maximal heart rate (HRmax) with 3-minute active breaks (~60 % HRmax) in between intervals, twice a week) on treadmills at the NextMove core facility at NTNU or to a control group. All participants will be provided with a pulse watch to keep after the study is completed. In addition, the participants will perform exercise once a week on their own following the correct exercise intensity. Pool training will be recommended based on potential benefits from compression. Body composition, blood pressure, VO2max (maximal oxygen uptake), questionnaire data and blood samples will be measured/collected before and after the exercise intervention. The participants will write a diary for their physical activity using standardized templates from the NextMove core facility.
Maximal oxygen uptake (VO2max) VO2max will be measured during uphill treadmill walking or running (Woodway PPS 55 Med, Munich, Germany), using ergospirometry (Jaeger, Oxycon pro, Hoechberg, Germany / Meta Max II, Cortex, Leipzig, Germany) as described earlier.11 A warm-up period for 10 min (~60% of HRmax) will precede the test. A levelling off of oxygen uptake (VO2) despite increased work load and respiratory exchange ratio ≥1.05 will be used as criteria for VO2max. HR will be measured continuously during the test (Polar, Polar Electro, Kempele, Finland), to define HRmax.
Anthropometric measurements Body weight, body mass index and waist-to-hip ratio will be measured. Body composition will be measured using InBody. For measurement of body composition, the investigators will use an instrument called Inbody 720 (Body Analysis AS). Inbody 720 provides weight, muscle mass, fat percentage, metabolism and mineral status non-invasively by sending weak electrical signals through the body. The whole test lasts just a few minutes. Before the analysis the participants should be fasten at least two hours and should avoid strenuous exercise. The standard procedures at NextMove will be used to measure the weight and height of participants. The height will be measured without shoes or head wear, this must be done with equal weight on both legs. The distance between the legs shall be a foot. The heels should be in the ground at full stretch their legs. The height is measured with one decimal. The weight is measured without heavy clothes and shoes, while the participants are standing still. It will be drawn 0.5 kg for the remaining clothes. The weight is measured with one decimal. The participants must stand upright for measuring of waist and hip circumference and a regular exhaust measuring the circumference one cm over the navel. The waist circumference is measured with no decimals.
Blood pressure Blood pressure will be measured while the patient is sitting down and have been resting for at least five minutes in a quiet room. It will be measured by a trained person, with a handheld sphygmomanometer (Tycos, 5098-02CB, USA). Blood pressure will be measured at the same time of the day for each individual at pre- and post test. The first reading will be discarded and the mean of the next three consecutive readings with a coefficient of variation below 15% will be used in the study, with additional readings if required. The sleeve should be placed at heart level and customized with the size of the participants arm.
Pain and fatigue registration Visual analog scale (VAS), measured by means of a 0-100 mm, for pain will be used to collect data on pain. VAS has been used in the social and behavioral sciences to measure a variety of subjective phenomena. A VAS is a straight line, whose end anchors indicate the extreme boundaries of the sensation, feeling, or responses to be measured. For example a VAS to measure pain can be labeled "no pain" on one end and "pain as bad as it could possibly be" on the other end. Subjects respond to the VAS by placing a mark through the line at a position which best represents their current perception of a given phenomenon between the labeled extremes. Although a VAS may be horizontal or vertical and of any length deemed appropriate, its most common form is a 100 mm horizontal line. The VAS is scored by measuring the distance, usually in millimeters, from one end of the scale to the subject's mark on the line. In the present study, a score from 1-100 was used for measuring self reported total pain and fatigue. LYMQOL (Lymphoedema Quality of Life) BEN and Brief Pain Inventory will be applied.
Quality of life questionnaires Short Form Health Survey-36 (SF-36) will be used to track potential changes in quality of life. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The eight sections are; vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health.
Standard blood analyses Blood collection and blood analyses will be performed using standard local procedures for the general biomarkers in clinical use and will be performed in all participants at the pre- and post-test. Three 3ml EDTA-tubes and one 3ml Li-heparin-tube will be collected and sent to clinical-chemical analyses at St.Olav's hospital. Parameters to be analyzed includes e.g. glucose, HbA1C, triglycerides, HDL-cholesterol, total cholesterol, serum ferritin and hs-CRP. An additional two tubes of blood (serum and EDTA) will be collected for later explorative biomarker assays. These blood samples will be centrifuged and aliquoted before freezing and storing in the LipidEx-biobank. A test from the standard laboratory that is without normal range may indicate a need for following up by a doctor, will be reported back to the participant as soon as possible, thus they will be asked to contact their general practitioner. The participants must fast at least three-hours before blood sampling. The time of last meal time for participants will be recorded on the patient form.
ELISA for lipedema biomarkers The ELISA technique can detect an amount of a given protein, antibody, or antigen in a sample. Explorative biomarkers outside clinical use will be assayd by ELISA methods established at the local laboratories at the Department of Circulation and Medical imaging. Potential biomarkers include TNFalpha, interleukines as well as PF4/CXCL4.
NMR Lipidomics/metabolomics/inflammatomics To explore the beneficial effects of HIIT on blood profile in these individuals, NMR (nuclear magnetic resonance) technology will be applied to determine if changes occur on the 1) lipoprotein subfractions that cannot be detected by measuring standard lipids, 2) changes occur in the metabolome and 3) changes occur in the inflammatory status. Lipidomics is a recently developed research area that apply different techniques to perform large-scale analyses of circulating lipids. NMR lipidomics utilizes differences in lipoprotein composition, size and density to extract information on lipoprotein subclasses. Several studies have demonstrated an association between lipoprotein subfractions and future cardiovascular health. This suggest that more refined analyses of lipoprotein subfractions may lead to further improvements in monitoring cardiovascular health. Lipidomics technology has developed rapidly over the past decade, to the point where clinical application now is possible.
Statistical power This is a pilot study, as there is very limited knowledge on exercise as treatment for lipedema. That is, no variables are available for power calculations. The investigators have chosen to set the number to 15 in each group to be able to account for up to 20% drop-outs. With the limited time available during a Master's project, this is a realistic target.
Data protection Patient information will be stored and handled in conformity with Norwegian laws and regulations.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Trondheim, Norway
- Institute for Circulation and Medical Imaging, NTNU
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- can meet for supervised exercise training in Trondheim.
Exclusion Criteria:
- eating disorders and/or orthopedic limitations for exercise training
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Exercise training
8 weeks of supervised high-intensity interval training (HIIT) that is 4×4 min intervals at 85-95% of maximal heart rate (HRmax) with 3-minute active breaks (~60 % HRmax) in between intervals, twice a week) on treadmills.
In addition, the participants will perform exercise once a week on their own following the correct exercise intensity.
|
8 weeks of supervised high-intensity interval training (HIIT).
|
|
No Intervention: Control
No intervention.
Carry on their normal life.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual analog scale (VAS)
Time Frame: Change from baseline to 8 weeks
|
Visual analog scale (VAS), measured by means of a 0-100 mm, for pain will be used to collect data on pain.
VAS has been used in the social and behavioral sciences to measure a variety of subjective phenomena.
A VAS is a straight line, whose end anchors indicate the extreme boundaries of the sensation, feeling, or responses to be measured.
For example, a VAS to measure pain can be labeled "no pain" on one end and "pain as bad as it could possibly be" on the other end.
Subjects respond to the VAS by placing a mark through the line at a position which best represents their current perception of a given phenomenon between the labeled extremes.
Although a VAS may be horizontal or vertical and of any length deemed appropriate, its most common form is a 100 mm horizontal line.
The VAS is scored by measuring the distance, usually in millimeters, from one end of the scale to the subject's mark on the line.
|
Change from baseline to 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
LYMQOL (Lymphoedema Quality of Life) legs
Time Frame: Change from baseline to 8 weeks
|
Self-reported questionnaire reporting quality of life adapted to lipedema patients. This questionnaire has been designed and validated for patients with chronic oedema/ lymphoedema of one or both legs to measure quality of life. The patients will tick the box that best describes how they feel about each of the questions.The questionaire includes 22 main questions. The patient may tick one of the following; "Not at all", "A little", "Quite a bit" or "A lot". The last question includes a scale. The title of the scale is "Overall, how would you rate your quality of life at present?". The minimum value is 0 and mean Poor, whereas the maximum value is 10 and means Excellent. |
Change from baseline to 8 weeks
|
|
Brief Pain Inventory
Time Frame: Change from baseline to 8 weeks
|
Self-reported questionnaire reporting pain. The Brief Pain Inventory is a validated, widely used, self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions. The title of the scale is pain. The BPI scale defines pain as follows: Worst Pain Score: 1 - 4 = Mild Pain. Worst Pain Score: 5 - 6 = Moderate Pain. Worst Pain Score: 7 - 10 = Severe Pain. |
Change from baseline to 8 weeks
|
|
Short Form Health Survey-36 (SF-36)
Time Frame: Change from baseline to 8 weeks
|
Self-reported questionnaire reporting quality of life.
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section.
Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight.
The lower the score the more disability.
|
Change from baseline to 8 weeks
|
|
Glucose
Time Frame: Change from baseline to 8 weeks
|
Serum levels of glucose
|
Change from baseline to 8 weeks
|
|
HbA1C
Time Frame: Change from baseline to 8 weeks
|
Serum levels of HbA1C
|
Change from baseline to 8 weeks
|
|
Triglycerides
Time Frame: Change from baseline to 8 weeks
|
Serum levels of triglycerides
|
Change from baseline to 8 weeks
|
|
HDL-cholesterol
Time Frame: Change from baseline to 8 weeks
|
Serum levels of HDL-cholesterol
|
Change from baseline to 8 weeks
|
|
Total cholesterol
Time Frame: Change from baseline to 8 weeks
|
Serum levels of total cholesterol
|
Change from baseline to 8 weeks
|
|
Ferritin
Time Frame: Change from baseline to 8 weeks
|
Serum levels of ferritin
|
Change from baseline to 8 weeks
|
|
hs-CRP
Time Frame: Change from baseline to 8 weeks
|
Serum levels of hs-CRP
|
Change from baseline to 8 weeks
|
|
Interleukin
Time Frame: Change from baseline to 8 weeks
|
Serum levels of interleukin
|
Change from baseline to 8 weeks
|
|
PF4/CXCL4
Time Frame: Change from baseline to 8 weeks
|
Serum levels of PF4/CXCL4
|
Change from baseline to 8 weeks
|
|
TNFalpha
Time Frame: Change from baseline to 8 weeks
|
Serum levels of TNFalpha
|
Change from baseline to 8 weeks
|
|
Protein levels in blood
Time Frame: Change from baseline to 8 weeks
|
Aprox.
200 proteins will be quantified (mmol/l) in blood by nuclear magnetic resonance.
|
Change from baseline to 8 weeks
|
|
Systolic blood pressure
Time Frame: Change from baseline to 8 weeks
|
Systolic blood pressure
|
Change from baseline to 8 weeks
|
|
Diastolic blood pressure
Time Frame: Change from baseline to 8 weeks
|
Diastolic blood pressure
|
Change from baseline to 8 weeks
|
|
Body weight
Time Frame: Change from baseline to 8 weeks
|
Body weight based on InBody 720
|
Change from baseline to 8 weeks
|
|
Muscle mass
Time Frame: Change from baseline to 8 weeks
|
Total muscle mass and in different parts of the body based on InBody 720
|
Change from baseline to 8 weeks
|
|
Fat percentage
Time Frame: Change from baseline to 8 weeks
|
Total fat percentage and in different parts of the body based on InBody 720
|
Change from baseline to 8 weeks
|
|
Resting metabolism
Time Frame: Change from baseline to 8 weeks
|
Whole body resting metabolism based on InBody 720
|
Change from baseline to 8 weeks
|
|
Maximal oxygen uptake
Time Frame: Change from baseline to 8 weeks
|
VO2max will be measured during uphill treadmill walking or running (Woodway PPS 55 Med, Munich, Germany), using ergospirometry (Jaeger, Oxycon pro, Hoechberg, Germany / Meta Max II, Cortex, Leipzig, Germany)
|
Change from baseline to 8 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Øivind Rognmo, PhD, Norwegian University of Science and Technology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 461077
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lipedema
-
Fatih Sultan Mehmet Training and Research HospitalCompletedLipedemaTurkey (Türkiye)
-
Istanbul Physical Medicine Rehabilitation Training...Completed
-
Cairo UniversityAvailable
-
Istanbul Physical Medicine Rehabilitation Training...Completed
-
Vanderbilt University Medical CenterCompleted
-
Hautklinik DarmstadtThe Clinical Trials Centre CologneActive, not recruiting
-
Primus PharmaceuticalsNortheastern UniversityCompleted
-
Cairo UniversityCompletedLipedema | Lower-Limb LipedemaEgypt
-
Gazi UniversityCompleted
-
Hitit UniversityCompleted
Clinical Trials on Exercise training
-
University of British ColumbiaMichael Smith Foundation for Health ResearchCompleted
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
Universidade Norte do ParanáCompleted
-
Universita di VeronaRecruiting
-
University of Colorado, DenverVA Eastern Colorado Health Care SystemCompletedHealthy | Overweight | Type 2 Diabetes Mellitus | Cardiovascular Risk FactorUnited States
-
National Taiwan University HospitalCompletedAtrial FibrillationTaiwan
-
Hacettepe UniversityCompleted
-
Toronto Rehabilitation InstituteCompletedAcute Myeloid LeukemiaCanada
-
University of LeipzigCompletedImpact of Intensive Exercise Training on Coronary Collateral Circulation in Patients With Stable CADStable Coronary Artery DiseaseGermany
-
Helse Stavanger HFStavanger Health ResearchCompletedVentricular TachycardiaNorway